Tag

Glp 1 Drugs

All articles tagged with #glp 1 drugs

business4 days ago•19 min saved

Disney Rolls Back Spousal Health Coverage Amid Rising Medical Costs

Disney will narrow spouses’ eligibility for Disney-sponsored health plans starting in 2027 if they can obtain coverage through their own employer, with children’s coverage and vision/dental plans staying the same. The move mirrors a broader corporate response to rising healthcare costs, including an 11% projected cost rise for 2027 and higher per-employee spend driven by drug costs, affecting about 160,000 Cast Members and reflecting trends seen at other large employers.

via The Hollywood Reporter|

#business #corporate-benefits #disney

health10 days ago•3 min saved

GLP-1 Weight-Loss Drugs Bring Big Benefits, New Risks as Trials Accelerate

GLP-1 weight-loss drugs show benefits beyond shedding pounds, including reduced inflammation, potential arthritis relief, and cardiovascular improvements, and may even curb alcohol cravings. However, they carry risks such as vitamin deficiencies, loss of eating enjoyment (hedonia), reduced appetite for food, and muscle/bone loss during weight loss, especially in frail patients. Off-label use in people who are not overweight poses safety concerns. A new triple-agonist drug, retatrutide, may deliver 25–30% weight loss—similar to bariatric surgery—but brings more side effects and is in Phase 3 trials, with potential approval in the coming years. Long-term success depends on continued use with diet/exercise; stopping reverses effects and weight tends to rebound.

via WAFB|

#glp-1-drugs #health #inflammation

business10 days ago•3 min saved

Hims & Hers CEO Defends FTC Case, Promises Cheaper GLP-1s and In-House AI

Hims & Hers CEO Andrew Dudum defends the company against an FTC lawsuit over data sharing and subscription practices, arguing the digital model increases access. He notes past price reductions from selling compounded GLP-1s, says Novo Nordisk dropped a patent suit and the firm now sells Novo’s branded drugs, and signals a move toward in-house AI to lower costs and transform healthcare.

via CNBC|

#ai-in-healthcare #business #drug-pricing

business12 days ago•2 min saved

Prescription prices plunge, but real patient savings remain unclear.

U.S. prescription drug prices fell 0.8% in July and are down 3.1% year over year—the steepest annual decline in more than six decades—driven by generic competition, GLP-1 price pressure, and price cuts tied to the Inflation Reduction Act and related Trump administration deals; but rebates are not fully captured in the CPI, and falling prices don't guarantee lower out-of-pocket costs as many Americans still struggle to afford medications.

via Axios|

#business #cpi #drug-prices

economy15 days ago•6 min saved

Record drop in U.S. prescription-drug prices driven by generics and policy moves

U.S. prescription-drug prices fell 2.7% over the past year through July—the steepest annual drop on record—driven by more generics, cheaper GLP-1 weight-loss drugs, and policy actions such as Medicare price negotiations; while the White House cites Trump-era price agreements as a factor, analysts say inflation-reduction policies and broader market dynamics are also at play, and the Bureau of Labor Statistics measure reflects actual paid prices, which can fall due to insurer deals or switching to cheaper drugs rather than outright price cuts by manufacturers.

via The Washington Post|

#economy #glp-1-drugs #inflation

health15 days ago•48 min saved

19-Year-Old Student Dies After Using Common GLP-1 Weight-Loss Drug

A 19-year-old law student from Corona, California, died in a London dorm after taking tirzepatide, a widely prescribed GLP-1/GIP weight‑loss drug sold as Mounjaro and Zepbound. An inquest found her death was due to cardiac arrhythmia, with doctors noting a congenital heart condition (myocardial bridging) that may have contributed; vomiting could have triggered electrolyte imbalances leading to the arrhythmia. Nasr had been prescribed Zepbound by a U.S. doctor and was not obese, highlighting potential risks associated with GLP-1 therapies.

via Yahoo|

#cardiac-arrhythmia #glp-1-drugs #health

health17 days ago•8 min saved

Off-Label GLP-1s Are Redefining PCOS Care, But Long-Term Use and Access Remain Unclear

An increasing number of women with PCOS/PMOS are using off-label GLP-1 drugs like Ozempic to address insulin resistance and metabolic symptoms, with many reporting improved cycles and weight loss; some studies also show higher pregnancy rates when GLP-1s are added to metformin. Yet there is no FDA-approved PMOS indication, insurance coverage is inconsistent and costly, and long-term durability of benefit and optimal treatment duration remain under study; guidelines still emphasize lifestyle changes and metformin as first-line therapy, while patient experiences and online communities highlight a gap between care and what patients are seeking.

via New York Post|

#glp-1-drugs #health #insulin-resistance

science20 days ago•7 min saved

Mosquito Attraction, Solar Whorls, and Evolution's Fecal Kickstart

ScienceAlert's This Week in Science rounds up: a FIU-led study finds some people attract more mosquitoes due to skin scents and microbes; the Sun’s surface is revealed in unprecedented detail with swirling vortices; researchers identify bacteria behind the 'farm effect' on immunity; humans are a predator even bears and mountain lions fear; GLP-1 drugs may lower the risk of age-related macular degeneration; and a review suggests ancient feces helped kickstart the evolution of complex life.

via ScienceAlert|

#evolution #farm-effect #glp-1-drugs

health21 days ago•8 min saved

England's Obesity Timebomb Worsens: 7.2 Million More Adults Obese Since 1993

A King's Fund analysis shows obesity in England has more than doubled since 1993, rising from 15% to 30% of adults, equating to 7.2 million additional people living with obesity. Despite 14 national strategies since 1992, rates have continued to climb, with a notable rise among 16–24-year-olds. While the NHS plans to expand access to GLP-1 weight-loss drugs, experts warn they are not a silver bullet and must be part of broader prevention efforts, including healthier food policies, supermarket standards, and empowering local authorities to address root causes and reduce health inequalities.

via lbc.co.uk|

#england #glp-1-drugs #health

health23 days ago•51 min saved

GLP-1 Weight-Loss Drugs Show Promising Eye Health Benefit in Seniors

A study of more than 157,000 obese adults without diabetes found GLP-1 receptor agonists (used for weight loss) are linked to an about 18% lower risk of developing age-related macular degeneration (AMD), rising to around 30% in unspecified AMD cases. The protective effect may stem from weight loss reducing systemic inflammation and oxidative stress, but the study is observational and short–term, so it cannot establish causation or mechanism. More research is needed to determine whether GLP-1s offer retinal protection or if weight loss itself drives the benefit.

via yahoo.com|

health25 days ago•6 min saved

GLP-1 Weight-Loss Drugs Show Potential to Lower Breast Cancer Recurrence

Observational findings presented at ASCO 2026 suggest GLP-1 medications (e.g., Ozempic, Wegovy) may be linked to lower breast cancer recurrence and possibly prevention, likely via weight loss and reduced inflammation; however, the evidence is not causative and randomized controlled trials are needed, with clinicians cautioning patients not to rely on GLP-1s solely for cancer risk reduction until proven.

via Fox News|

#breast-cancer #glp-1-drugs #health

health1 month ago•1 min saved

Brides Turn to GLP-1 Weight-Loss Drugs to Fit the Dress

Obesity specialists say GLP-1 weight-loss medications are becoming a wedding trend, with brides like Laura Patnaude losing about 25 pounds to fit into a gown—though experts note caution, as 40 pounds would be risky for the dress and health.

via The Boston Globe|

#bridal-fashion #glp-1-drugs #health

health1 month ago•50 min saved

Two Decades of GLP-1s: Obesity, Economy, and Culture in the Ozempic Era

A BuzzFeed News piece gathers Reddit discussions and user anecdotes to explore how GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) could reshape society over 20 years. Predictions span obesity becoming a “disease of poverty,” shifts in beauty standards toward muscle or other traits, and the role of patent expirations and pricing in global access. The article also highlights potential economic and geopolitical effects, factory shifts in the food and insurance industries, and debates over long‑term health impacts and craving dynamics, all illustrating a future where widespread GLP-1 use could alter health, wealth, and culture.

via BuzzFeed|

#drug-pricing #glp-1-drugs #health

future-perfect1 month ago•30 min saved

US life expectancy edges toward an all-time high as overdoses drop

CDC provisional data show the US death rate fell to a record low in 2025 (689.2 per 100,000), with life expectancy likely reaching a new high after hitting 79 years in 2024. The turnaround is driven largely by a sharp decline in overdose deaths (about 70,000 in 2025, down from 114,000 in 2023), plus declines in homicides and Covid deaths, and broad gains in heart disease and cancer mortality. GLP-1 obesity drugs could push life expectancy even higher, but the US still trails peer nations by about 3–4 years and features wide state- and income-related disparities.

via vox.com|

#future-perfect #glp-1-drugs #health-disparities

health1 month ago•2 min saved

Medicare Expands GLP-1 Coverage to Weight Loss at $50 Copay, Anchoring a New Health-Economy Shift

Medicare’s one-year Bridge Program now covers GLP-1 weight-loss medications (Foundayo, Wegovy, or Zepbound) for a $50 copay, extending access beyond diabetics to those with BMI 35+ or 27+ with conditions. The move could be a watershed for obesity treatment and trigger broader economic and policy shifts as demand and costs rise.

via vox.com|

#glp-1-drugs #health #health-policy